|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:ATCCode
|
gptkb:J05AP08
|
|
gptkbp:brand
|
gptkb:Vosevi
gptkb:Harvoni
gptkb:Sovaldi
Epclusa
|
|
gptkbp:CASNumber
|
1190307-88-0
|
|
gptkbp:contraindication
|
severe bradycardia with amiodarone
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:developer
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugInteraction
|
gptkb:rifampin
gptkb:St._John's_Wort
amiodarone
|
|
gptkbp:eliminationHalfLife
|
0.4 hours (sofosbuvir), 27 hours (GS-331007)
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasInChIKey
|
YYOQXSRSLFDYER-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C22H29FN3O9P
|
|
gptkbp:hasSMILES
|
CC(C)COC(=O)[C@H](NP(=O)(OC[C@H]1O[C@@](C#N)([C@H](O)[C@@H]1O)F)Oc2ccccc2)C(C)C
|
|
gptkbp:hasUNII
|
SOF2X721MH
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB09241
|
|
gptkbp:indication
|
treatment of chronic hepatitis C infection
|
|
gptkbp:isAntiviral
|
true
|
|
gptkbp:isProdrug
|
true
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:listedOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:mechanismOfAction
|
inhibits HCV NS5B polymerase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
529.45
|
|
gptkbp:name
|
gptkb:Sofosbuvir
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
N (US)
|
|
gptkbp:PubChem_CID
|
gptkb:DB09241
45375808
D09964
CHEMBL1257078
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
headache
insomnia
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:GS-7977
gptkb:PSI-7977
Sofosbuvirum
|
|
gptkbp:target
|
NS5B RNA-dependent RNA polymerase
|
|
gptkbp:bfsParent
|
gptkb:Methylene_blue
|
|
gptkbp:bfsLayer
|
6
|